Juvenescence’s Latest Venture, MDI Therapeutics, Inc., Targeting Fibrotic Disease
A biopharmaceutical company focused on treating aging and age-related disease
BBC Science Focus Magazine: An End To Aging?
The human suffering is huge, and in the next 30 years, the number of over-65-year-olds is projected to double to 1.5 billion.
Forbes: AI And Optimism: Jim Mellon Wants Us All To Live Longer
Jim Mellon probably has a broader understanding of the progress being made confronting human aging than any other person alive.
Ro5 Bioactivity Lab: Identification of Drug Candidates for COVID-19
The public health emergency known as the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has […]
Longevity Technology: ‘Greg Bailey on Democratizing Healthcare, Paradigm Shifts & Disruptive Technologies’
Dr. Bailey discusses the origins of Juvenescence as well as his belief that the nascent longevity industry is reaching an inflection point.
Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments
Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
Juvenescence Capitalizes BYOMass
Juvenescence is pleased to announce its latest equity investment in BYOMass Inc.
Juvenescence, The Buck Institute, and Insilico Medicine establish Napa Therapeutics
The Buck Institute is one of the leading research centers in the world focused solely on research on aging and the elimination of age-related disease.